Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation

Phase 2

Terminated

Conditions: Hematologic Malignancies

Interventions: Procedure: Haploidentical Transplant
Drug: Fludarabine
Drug: Busulfan
Radiation: Total Body Irradiation
Drug: Cyclophosphamide

First Posted Date: 2012-12-13

Last Posted Date: 2020-02-25

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 3

Registration Number: NCT01749293

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

Phase 2

Terminated

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Acute Lymphocytic Leukemia
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Interventions: Device: CliniMACS® CD34 Reagent System
Drug: Fludarabine
Drug: Melphalan
Procedure: Double Umbilical Cord Blood Transplantation
Drug: Rabbit ATG
Procedure: Haplo-Identical Cord Transplantation

First Posted Date: 2012-12-10

Last Posted Date: 2018-07-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 2

Registration Number: NCT01745913

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions: Biological: Aldesleukin
Biological: CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Biological: NGFR-transduced Autologous T Lymphocytes
Other: Quality-of-Life Assessment

First Posted Date: 2012-12-04

Last Posted Date: 2024-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT01740557

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
de Novo Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndromes

Interventions: Drug: decitabine
Drug: fludarabine phosphate
Drug: busulfan
Drug: cyclophosphamide
Drug: tacrolimus
Drug: mycophenolate mofetil
Biological: filgrastim
Radiation: total-body irradiation
Procedure: allogeneic bone marrow transplantation
Other: laboratory biomarker analysis

First Posted Date: 2012-10-15

Last Posted Date: 2019-11-21

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 20

Registration Number: NCT01707004

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Leukemia of Ambiguous Lineage
Acute Myeloid Leukemia

Interventions: Biological: Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
Drug: Cytarabine
Drug: Filgrastim
Drug: Fludarabine Phosphate

First Posted Date: 2012-10-05

Last Posted Date: 2019-03-01

Lead Sponsor: Nohla Therapeutics, Inc.

Target Recruit Count: 7

Registration Number: NCT01701323

Locations: 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Not Applicable

Active, not recruiting

Conditions: Metastatic Melanoma

Interventions: Drug: Ipilimumab
Procedure: Tumor Infiltrating Lymphocytes (TIL)
Drug: Administration of Lymphodepletion
Drug: Cyclophosphamide as Part of Lymphodepletion
Drug: Fludarabine as Part of Lymphodepletion
Drug: High Dose IL-2
Biological: Adoptive Cell Therapy with TIL

First Posted Date: 2012-10-05

Last Posted Date: 2024-12-16

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 13

Registration Number: NCT01701674

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Phase 2

Active, not recruiting

Conditions: Malignant Neoplasm

Interventions: Biological: aldesleukin
Drug: fludarabine phosphate
Drug: cyclophosphamide
Other: laboratory biomarker analysis
Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Biological: dendritic cell vaccine therapy
Radiation: fludeoxyglucose F 18
Procedure: positron emission tomography

First Posted Date: 2012-10-02

Last Posted Date: 2024-11-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT01697527

Locations: 🇺🇸
University of California at Los Angeles (UCLA ), Los Angeles, California, United States

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia in Remission
Chronic Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Cyclophosphamide
Drug: Cyclosporine
Biological: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Drug: Thiotepa
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2012-09-21

Last Posted Date: 2021-07-06

Lead Sponsor: Nohla Therapeutics, Inc.

Target Recruit Count: 163

Registration Number: NCT01690520

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 5 locations

High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment

Phase 2

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: Alemtuzumab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2012-09-05

Last Posted Date: 2013-11-25

Lead Sponsor: Seah Lim M.D.

Target Recruit Count: 1

Registration Number: NCT01679041

Locations: 🇺🇸
Texas Oncology, Amarillo, Texas, United States
🇺🇸
Dr Ruby Saulog, Amarillo, Texas, United States
🇺🇸
Amarillo Diagnostic Clinic, Amarillo, Texas, United States

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

Not Applicable

Recruiting

Conditions: Immunodeficiencies
Hemoglobinopathies
Hematologic Disorders

Interventions: Drug: Busulfan
Drug: Fludarabine
Radiation: Total body irradiation
Biological: Stem cell transplant
Drug: Keppra

First Posted Date: 2012-08-16

Last Posted Date: 2024-07-19

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 30

Registration Number: NCT01666080

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy